DJIA: 47,851
Every dog will have its day… even the Russell 2000. Obviously we’re not fans here, having unkindly referred to it as love among the rejects. The Russell is comprised of companies not growing and therefore not able to move on to the grown-up indexes. And then there are all those Financials, making it a bit of a proxy for rates. That’s not a bad thing as an indicator, but not exactly a gauge for growth. They call it a measure of secondary stock behavior, and from time to time it is. Last month it was especially so. While Tech stocks played the role of drama queen, the Russell managed an unusual and very bullish reversal pattern, going from a one-month low to a one-month high, in a remarkable 10 days. Doing so bodes well for upcoming months. Overall, this looks more like a shift than any dramatic change in leadership. Interesting, though, the S&P Pure Growth ETF versus the Pure Value ETF does say change.
The good news about the Russell is good news all around, in that these reversals are positive for the S&P as well. For the Russell, however, the added kicker is “tis the season,” with already some signs of a January effect come early. Keep in mind the averages hardly tell the whole story here of stocks which over the year have come and gone, so to speak. Bitcoin itself, Bitcoin Miners, the Quantum stocks, all battered and looking for some relief. As for market leadership, Tech, the Mag7, Nvidia (NVDA – 183) and Palantir (PLTR – 178) are just fine, just in need of a little rest. What has separated out a bit are a few Techs like Applied Materials (AMAT – 269) and ASML (1110), the guys that made the stuff to make the stuff. Back in mid-November AMAT gapped down on bad news only to close unchanged on the day. That sort of action always gets our attention.
In a sense, it’s rotation that has kept this market alive and well, technically speaking. The good part recently has been the strength in Healthcare altogether, and Biotech particularly. And there’s a lot there, big and small, good for market breadth and the averages. The dark side of the rotational market has been the weakness in Energy, not so much Oil and Gas energy, AI energy from Utilities to Uranium. And to look at stocks like Nuscale (SMR – 23), OKLO (112) or ETFs like URNM (60) and NLR (139), rotation is a euphemism. These could be candidates for yearend strength. Unlike others, Vertiv (VRT – 183) and Comfort Systems (FIX – 1005) do act well, and are an integral part of the AI story. Another might be Bloom Energy (BE – 118), down from its recent high, but dancing around its 50-day moving average, better than most. A close above Monday’s high around 115 should mean a resumption of the uptrend. Also, we noticed the pattern similar to MongoDB (MDB – 397) before its recent gap higher.
In terms of big Pharma, Eli Lilly (LLY – 1013) already seems the leader. We know of price targets some 500 points higher, and the chart does support that. The rub, of course, is when? The stock currently is roughly 150 points above even its 50-day moving average. Stocks all have their own character, extended for one as measured by this or that differs from another. The aforementioned BE was at one point more than 50% above its 50-day when it corrected, but again stocks differ. Important too, corrections come in two forms – weakness, and consolidations. Stocks can simply stall out until the relevant moving average catches up, so to speak. This may not be the best entry point, but it seems a stock you could consider.
November wasn’t fun but as the saying goes, all is well that ends well. And November ended well, with five consecutive positive days in the advance-decline numbers, a couple of which were quite impressive. This followed five of six down days, suggesting we may have seen a bit of a washout. As always the key is follow through – so far so good. Down days like Monday happen, worry more about the bad up days, when the average stock lags the stock averages. Long ago what piqued our interest in technical versus funnymental analysis is quite simple. We noticed when the overall market went up our stocks went up and vice versa. IBD like other studies holds that up to 70% of the movement in individual stocks is a function of the market’s overall trend. Certainly it has been a good year for the market, for groups it has seemed more the movable feast, even within Tech. Now comes December with its usual crosscurrents, likely more lift in the downtrodden.
Frank D. Gretz
Click to Download